NICE recommends innovative treatment for type 1 diabetes


12 July 2019 - It’s estimated that around 90,000 people could be eligible for treatment with dapagliflozin.

NICE has today issued draft final guidance on dapagliflozin with insulin for treating type 1 diabetes.

Around 8% of people with diabetes in the UK have type 1 diabetes. It’s a serious lifelong condition which is caused when the level of glucose (sugar) in the person’s blood is too high because their body cannot produce enough insulin. It is not caused by someone’s diet or lifestyle and its origin is unknown. Daily injections of insulin are needed to keep a person’s blood glucose levels under control.

Read NICE press release

Michael Wonder

Posted by:

Michael Wonder